All Stories

  1. Myocardial revascularization with percutaneous coronary intervention: To complete or not to complete?
  2. Stent selection to minimize the risk of stent thrombosis
  3. Validation and Comparison of the Long-Term Prognostic Capability of the SYNTAX Score-II Among 1,528 Consecutive Patients Who Underwent Left Main Percutaneous Coronary Intervention
  4. Impact of Gene Polymorphisms, Platelet Reactivity, and the SYNTAX Score on 1-Year Clinical Outcomes in Patients With Non–ST-Segment Elevation Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention
  5. SYNTAX score and the risk of stent thrombosis after percutaneous coronary intervention in patients with non‐ST‐segment elevation acute coronary syndromes: An ACUITY trial substudy
  6. Risk of Stroke in Patients With High On-Clopidogrel Platelet Reactivity to Adenosine Diphosphate After Percutaneous Coronary Intervention
  7. Percutaneous coronary intervention versus coronary artery bypass graft for stable angina: Meta-regression of randomized trials
  8. Ischemic Outcomes After Coronary Intervention of Calcified Vessels in Acute Coronary Syndromes
  9. Impact of Coronary Lesion Complexity on Drug-Eluting Stent Outcomes in Patients With and Without Diabetes Mellitus
  10. Usefulness of the SYNTAX Score to Predict Acute Kidney Injury After Percutaneous Coronary Intervention (from the Acute Catheterization and Urgent Intervention Triage Strategy Trial)
  11. Relation Between Coronary Calcium and Major Bleeding After Percutaneous Coronary Intervention in Acute Coronary Syndromes (from the Acute Catheterization and Urgent Intervention Triage Strategy and Harmonizing Outcomes With Revascularization and Stents...
  12. Clinical Outcomes With Bioabsorbable Polymer- Versus Durable Polymer-Based Drug-Eluting and Bare-Metal Stents
  13. Prognostic Utility of the SYNTAX Score in Patients With Single Versus Multivessel Disease Undergoing Percutaneous Coronary Intervention (from the Acute Catheterization and Urgent Intervention Triage StrategY [ACUITY] Trial)
  14. Detection of Tissue Factor Antigen and Coagulation Activity in Coronary Artery Thrombi Isolated from Patients with ST-Segment Elevation Acute Myocardial Infarction
  15. Relation Between White Blood Cell Count and Final Infarct Size in Patients With ST-Segment Elevation Acute Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention (from the INFUSE AMI Trial)
  16. Stent Thrombosis With Drug-Eluting Stents
  17. TCT-225 Relationship Between the SYNTAX Score and Major Bleeding after PCI: Analysis from the ACUITY Trial
  18. TCT-19 The Impact of Coronary Lesion Severity on Drug-eluting Stent Outcomes in Patients with and without Diabetes Mellitus
  19. TCT-322 Utility of the Residual SYNTAX Score In Patients With Diabetes Mellitus After Percutaneous Coronary Intervention
  20. TCT-467 The SYNTAX Score And Risk Of Stent Thrombosis In Patients Undergoing PCI For NSTE-ACS: An ACUITY Trial PCI Cohort Analysis
  21. TCT-341 The SYNTAX Score Predicts Acute Kidney Injury After PCI for NSTEACS: Analysis from the ACUITY Trial
  22. Prediction of Coronary Risk by SYNTAX and Derived Scores
  23. Response to letter by Messeri et al
  24. Network meta-analyses and mixed treatment comparisons: Are they true scientific endeavors?
  25. Clinical Outcomes With Drug-Eluting and Bare-Metal Stents in Patients With ST-Segment Elevation Myocardial Infarction
  26. Prediction of 1-Year Mortality in Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention
  27. Risk of stroke with percutaneous coronary intervention compared with on-pump and off-pump coronary artery bypass graft surgery: Evidence from a comprehensive network meta-analysis
  28. Predictors of complicated athero-thrombotic lesions in non-ST segment acute coronary syndrome
  29. Predictors of suboptimal TIMI flow after primary angioplasty for acute myocardial infarction: results from the HORIZONS-AMI trial
  30. Association Among Leukocyte Count, Mortality, and Bleeding in Patients With Non–ST-Segment Elevation Acute Coronary Syndromes (from the Acute Catheterization and Urgent Intervention Triage StrategY [ACUITY] Trial)
  31. Emerging indications, in-hospital and long-term outcome of balloon aortic valvuloplasty in the transcatheter aortic valve implantation era
  32. PREDICTION OF ONE-YEAR MORTALITY IN PATIENTS WITH ACUTE CORONARY SYNDROMES UNDERGOING PCI FROM THE ACUITY (ACUTE CATHETERIZATION AND URGENT INTERVENTION TRIAGE STRATEGY) TRIAL VALIDATION OF THE LOGISTIC CLINICAL SYNTAX SCORE
  33. IMPACT OF CORONARY CALCIFICATION ON ONE–YEAR OUTCOMES AFTER PCI IN STEMI AND NSTEMI: POOLED ANALYSIS FROM HORIZONS AND ACUITY TRIALS
  34. ASSOCIATION BETWEEN CORONARY CALCIFICATION AND BLEEDING AFTER PCI IN ACS: POOLED ANALYSIS FROM HORIZONS-AMI AND ACUITY TRIALS
  35. Prognostic Significance of Baseline White Blood Cell Count in Patients with Non-ST-Segment Elevation Acute Coronary Syndrome
  36. Baseline White Blood Cell Count Is an Independent Predictor of Long-Term Cardiovascular Mortality in Patients with Non-ST-Segment Elevation Acute Coronary Syndrome, but It Does Not Improve the Risk Classification of the GRACE Score
  37. A New Score for Risk Stratification of Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention
  38. TCT-670 Impact of Moderate and Severe Coronary Calcification on 1-Year Outcomes after PCI with DES: A Pooled Analysis of 11,651 Patients from 14 Randomized Trials
  39. TCT-486 Relationship Between White Blood Cell Count and Final Infarct Size in Patients with ST-Segment Elevation Acute Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention: Analysis from the INFUSE-AMI Trial
  40. Stent thrombosis with drug-eluting and bare-metal stents – Authors' reply
  41. Risk of Stroke With Coronary Artery Bypass Graft Surgery Compared With Percutaneous Coronary Intervention
  42. Quantification and Impact of Untreated Coronary Artery Disease After Percutaneous Coronary Intervention
  43. Incidence, treatment and outcome of acute coronary syndromes: A community-based study in the era of myocardial infarction networks
  44. Residual aortic regurgitation is a major determinant of late mortality after transcatheter aortic valve implantation
  45. Defining high-risk patients with ST-segment elevation acute myocardial infarction undergoing primary percutaneous coronary intervention: A comparison among different scoring systems and clinical definitions
  46. Revascularization of unprotected left main coronary artery disease: Strategy selection and systematic risk assessment
  47. Stent thrombosis with drug-eluting and bare-metal stents: evidence from a comprehensive network meta-analysis
  48. INCIDENCE, PREDICTORS AND IMPACT OF STROKE IN ACUTE CORONARY SYNDROME: INSIGHTS FROM THE ACUITY TRIAL
  49. QUANTIFICATION AND IMPACT OF UNTREATED CORONARY ARTERY DISEASE AFTER PCI: THE RESIDUAL SYNTAX SCORE
  50. Comparison of clinical and angiographic prognostic risk scores in patients with acute coronary syndromes: Analysis from the Acute Catheterization and Urgent Intervention Triage StrategY (ACUITY) trial
  51. Percutaneous revascularization of left main
  52. A Guide to Calculating SYNTAX Score
  53. Radial access in patients with ST-segment elevation myocardial infarction undergoing primary angioplasty in acute myocardial infarction: the HORIZONS-AMI trial
  54. Is balloon aortic valvuloplasty safe in patients with significant aortic valve regurgitation?
  55. Impact of a territorial ST-segment elevation myocardial infarction network on prognosis of patients with out-of-hospital cardiac arrest
  56. Pre-hospital ECG in patients undergoing primary percutaneous interventions within an integrated system of care: reperfusion times and long-term survival benefits
  57. Short- and Long-Term Prognostic Significance of ST-Segment Elevation in Lead aVR in Patients With Non–ST-Segment Elevation Acute Coronary Syndrome
  58. Prognostic Value of the SYNTAX Score in Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention
  59. SHORT AND LONG-TERM PROGNOSTIC SIGNIFICANCE OF ST-SEGMENT ELEVATION IN LEAD AVR IN PATIENTS WITH NON-ST-SEGMENT ELEVATION ACUTE CORONARY SYNDROME
  60. COMPARISON OF THE PROGNOSTIC UTILITY OF VARIOUS CLINICAL AND ANGIOGRAPHIC RISK SCORES IN PATIENTS WITH ACUTE CORONARY SYNDROMES: ANALYSIS FROM THE ACUITY TRIAL
  61. PROGNOSTIC UTILITY OF THE SYNTAX SCORE IN PATIENTS WITH SINGLE VS. MULTIVESSEL DISEASE UNDERGOING PERCUTANEOUS CORONARY INTERVENTION: INSIGHTS FROM THE ACUITY TRIAL
  62. Risks of Stroke After Coronary Artery Bypass Graft – Recent Insights and Perspectives
  63. Appraising the impact of left ventricular ejection fraction on outcomes of percutaneous drug-eluting stenting for unprotected left main disease: insights from a multicenter registry of 975 patients
  64. Predictive value of C-reactive protein on 30-day and 1-year mortality in acute coronary syndromes: an analysis from the ACUITY trial
  65. How many patients with severe symptomatic aortic stenosis excluded for cardiac surgery are eligible for transcatheter heart valve implantation?
  66. NT pro-B-type natriuretic peptide levels are related to microvascular reperfusion in patients undergoing direct percutaneous transluminal coronary angioplasty for anterior ST-segment elevation myocardial infarction
  67. A randomised study comparing the antiplatelet and antinflammatory effect of clopidogrel 150mg/day versus 75mg/day in patients with ST-segment elevation acute myocardial infarction and poor responsiveness to clopidogrel: Results from the DOUBLE study
  68. Prognostic Implications of ST-Segment Elevation Resolution in Patients With ST-Segment Elevation Acute Myocardial Infarction Treated With Primary or Facilitated Percutaneous Coronary Intervention
  69. Sex-related differences in patients undergoing percutaneous unprotected left main stenting
  70. Lower long-term mortality within a regional system of care for ST-elevation myocardial infarction
  71. Impact of Acute Coronary Syndromes on Two-Year Clinical Outcomes in Patients With Unprotected Left Main Coronary Artery Stenosis Treated With Drug-Eluting Stents
  72. Prognostic Importance of Ventricular Arrhythmia in Patients Treated With Percutaneous Coronary Intervention
  73. Temporal Pattern of Ischemic Events in Relation to Dual Antiplatelet Therapy in Patients With Unprotected Left Main Coronary Artery Stenosis Undergoing Percutaneous Coronary Intervention
  74. Long‐term clinical benefit of drug‐eluting stents over bare‐metal stents in diabetic patients with de novo left main coronary artery disease: Results from a real‐world multicenter registry
  75. Comparison of Drug-Eluting Stents and Bare-Metal Stents for the Treatment of Unprotected Left Main Coronary Artery Disease in Acute Coronary Syndromes
  76. Two-Year Clinical Outcome With Drug-Eluting Stents Versus Bare-Metal Stents in a Real-World Registry of Unprotected Left Main Coronary Artery Stenosis from the Italian Society of Invasive Cardiology
  77. Usefulness of Prehospital Triage in Patients With Cardiogenic Shock Complicating ST-Elevation Myocardial Infarction Treated With Primary Percutaneous Coronary Intervention
  78. Clinical comparison of “normal-hours” vs “off-hours” percutaneous coronary interventions for ST-elevation myocardial infarction
  79. Randomized comparative trial of a thin‐strut bare metal cobalt‐chromium stent versus a sirolimus‐eluting stent for coronary revascularization
  80. Preoperative C-reactive protein levels predict 9-month mortality after coronary artery bypass grafting surgery for the treatment of left main coronary artery stenosis
  81. Comparison Between Coronary Angioplasty and Coronary Artery Bypass Surgery for the Treatment of Unprotected Left Main Coronary Artery Stenosis (the Bologna Registry)
  82. Clinical imaging of the vulnerable plaque in the coronary arteries: new intracoronary diagnostic methods
  83. 32P Brachytherapy in the Treatment of Complex Cypher In‐Stent Restenosis
  84. Long‐term clinical and angiographic outcome of patients with occlusive in‐stent restenosis treated with (32P) β‐brachytherapy
  85. Monocyte-derived tissue factor contributes to stent thrombosis in an in vitro system
  86. Effects of abciximab on the acute pathology of blood vessels after arterial stenting in nonhuman primates
  87. Coronary stenting for unstable angina
  88. Coronary stenting for unstable angina
  89. Coronary stenting with the half (disarticulated) Palmaz-Schatz stent: Immediate results and six-month follow-up
  90. Results of coronary stenting for unstable versus stable angina pectoris